Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Eur J Pharmacol. 2018 Jan 5;818:103-109. doi: 10.1016/j.ejphar.2017.10.049. Epub 2017 Oct 21.
Glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors (collectively termed incretin-based therapies) represent two of the most widely used classes of antidiabetic drugs. These compounds exert their beneficial effects on carbohydrate metabolism through the activation of specific glucagon like peptide-1 receptors in various organs. Accumulating evidence suggests that glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors also affect renal function in both glucagon like peptide-1 receptor-dependent and independent manner. However, the clinical significance of these observations remains indeterminate. In this review, we summarize the available preclinical and clinical data on the effects of incretin-based therapies on renal function indices and discuss their relevance in everyday clinical practise.
胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂（统称为基于肠促胰岛素的治疗药物）是两种应用最广泛的抗糖尿病药物。这些化合物通过在各种器官中激活特定的胰高血糖素样肽-1 受体，对碳水化合物代谢发挥有益作用。越来越多的证据表明，胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂也以胰高血糖素样肽-1 受体依赖和非依赖的方式影响肾功能。然而，这些观察结果的临床意义仍不确定。在这篇综述中，我们总结了关于基于肠促胰岛素的治疗药物对肾功能指标影响的现有临床前和临床数据，并讨论了它们在日常临床实践中的相关性。
